Misplaced Pages

This is an old revision of this page, as edited by MusikAnimal (talk | contribs) at 20:54, 8 October 2013 (Reverted 1 edit by 50.79.221.140 identified as test/vandalism using STiki). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Cardiovascular disease
Specialty	Cardiology

Cardiovascular disease (also called heart disease) is a class of diseases that involve the heart, the blood vessels (arteries, capillaries, and veins) or both.

Cardiovascular disease refers to any disease that affects the cardiovascular system, principally cardiac disease, vascular diseases of the brain and kidney, and peripheral arterial disease. The causes of cardiovascular disease are diverse but atherosclerosis and/or hypertension are the most common. Additionally, with aging come a number of physiological and morphological changes that alter cardiovascular function and lead to subsequently increased risk of cardiovascular disease, even in healthy asymptomatic individuals.

Cardiovascular disease is the leading cause of deaths worldwide, though since the 1970s, cardiovascular mortality rates have declined in many high-income countries. At the same time, cardiovascular deaths and disease have increased at a fast rate in low- and middle-income countries. Although cardiovascular disease usually affects older adults, the antecedents of cardiovascular disease, notably atherosclerosis, begin in early life, making primary prevention efforts necessary from childhood. There is therefore increased emphasis on preventing atherosclerosis by modifying risk factors, such as healthy eating, exercise, and avoidance of smoking tobacco.

Types

• Coronary artery disease ( also known as coronary heart disease and ischaemic heart disease)
• Cardiomyopathy - diseases of cardiac muscle
• Hypertensive heart disease - diseases of the heart secondary to high blood pressure
• Heart failure
• Cor pulmonale - a failure at the right side of the heart with respiratory system involvement
• Cardiac dysrhythmias - abnormalities of heart rhythm
• Inflammatory heart disease
  • Endocarditis – inflammation of the inner layer of the heart, the endocardium. The structures most commonly involved are the heart valves.
  • Inflammatory cardiomegaly
  • Myocarditis – inflammation of the myocardium, the muscular part of the heart.
• Valvular heart disease
• Cerebrovascular disease - disease of blood vessels that supplies to the brain such as stroke
• Peripheral arterial disease - disease of blood vessels that supplies to the arms and legs
• Congenital heart disease - heart structure malformations existing at birth
• Rheumatic heart disease - heart muscles and valves damage due to rheumatic fever caused by streptococcal bacteria infections

Risk factors

Evidence suggests a number of risk factors for heart disease: age, gender, high blood pressure, high serum cholesterol levels, tobacco smoking, excessive alcohol consumption, sugar consumption, family history, obesity, lack of physical activity, psychosocial factors, diabetes mellitus, air pollution. While the individual contribution of each risk factor varies between different communities or ethnic groups the consistency of the overall contribution of these risk factors to epidemiological studies is remarkably strong. Some of these risk factors, such as age, gender or family history, are immutable; however, many important cardiovascular risk factors are modifiable by lifestyle change, drug treatment or social change.

Age

Age is by far the most important risk factor in developing cardiovascular diseases, with approximately a tripling of risk with each decade of life. It is estimated that 87 percent of people who die of coronary heart disease are 60 and older. At the same time, the risk of stroke doubles every decade after age 55.

Multiple explanations have been proposed to explain why age increases the risk of cardiovascular diseases. One of them is related to serum cholesterol level. In most populations, the serum total cholesterol level increases as age increases. In men, this increase levels off around age 45 to 50 years. In women, the increase continues sharply until age 60 to 65 years.

Aging is also associated with changes in the mechanical and structural properties of the vascular wall, which leads to the loss of arterial elasticity and reduced arterial compliance and may subsequently lead to coronary artery disease.

Sex

Men are at greater risk of heart disease than pre-menopausal women. Once past menopause, it has been argued that a woman's risk is similar to a man's although more recent data from the WHO and UN disputes this.

Among middle-aged people, coronary heart disease is 2 to 5 times more common in men than in women. In a study done by the World Health Organization, sex contributes to approximately 40% of the variation in the sex ratios of coronary heart disease mortality. Another study reports similar results that gender difference explains nearly half of the risk associated with cardiovascular diseases One of the proposed explanations for the gender difference in cardiovascular disease is hormonal difference. Among women, estrogen is the predominant sex hormone. Estrogen may have protective effects through glucose metabolism and hemostatic system, and it may have a direct effect on improving endothelial cell function. The production of estrogen decreases after menopause, and may change the female lipid metabolism toward a more atherogenic form by decreasing the HDL cholesterol level and by increasing LDL and total cholesterol levels. Women who have experienced early menopause, either naturally or because they have had a hysterectomy, are twice as likely to develop heart disease as women of the same age group who have not yet gone through menopause.

Among men and women, there are differences in body weight, height, body fat distribution, heart rate, stroke volume, and arterial compliance. In the very elderly, age related large artery pulsatility and stiffness is more pronounced in women. This may be caused by the smaller body size and arterial dimensions independent of menopause.

Air pollution

Particulate matter has been studied for its short- and long-term exposure effects on cardiovascular disease. Currently, PM_2.5 is the major focus, in which gradients are used to determine CVD risk. For every 10 μg/m of PM_2.5 long-term exposure, there was an estimated 8-18% CVD mortality risk. Women had a higher relative risk (RR) (1.42) for PM_2.5 induced coronary artery disease than men (0.90) did. Overall, long-term PM exposure increased rate of atherosclerosis and inflammation. In regards to short-term exposure (2 hours), every 25 μg/m of PM_2.5 resulted in a 48% increase of CVD mortality risk. Additionally, after only 5 days of exposure, a rise in systolic (2.8 mmHg) and diastolic (2.7 mmHg) blood pressure occurred for every 10.5 μg/m of PM_2.5. Other research has implicated PM_2.5 in irregular heart rhythm, reduced heart rate variability (decreased vagal tone), and most notably heart failure. PM_2.5 is also linked to carotid artery thickening and increased risk of acute myocardial infarction.

Pathophysiology

Population based studies show that atherosclerosis the major precursor of cardiovascular disease begins in childhood. The Pathobiological Determinants of Atherosclerosis in Youth Study demonstrated that intimal lesions appear in all the aortas and more than half of the right coronary arteries of youths aged 7–9 years.

This is extremely important considering that 1 in 3 people will die from complications attributable to atherosclerosis. In order to stem the tide education and awareness that cardiovascular disease poses the greatest threat and measures to prevent or reverse this disease must be taken.

Obesity and diabetes mellitus are often linked to cardiovascular disease, as are a history of chronic kidney disease and hypercholesterolaemia. In fact, cardiovascular disease is the most life threatening of the diabetic complications and diabetics are two- to four-fold more likely to die of cardiovascular-related causes than nondiabetics.

Screening

Screening ECGs (either at rest or with exercise) are not recommended in those without symptoms who are at low risk. In those at higher risk the evidence for screening with ECGs is inconclusive.

Some biomarkers may add to conventional cardiovascular risk factors in predicting the risk of future cardiovascular disease; however, the clinical value of some biomarkers is still questionable. Currently, biomarkers which may reflect a higher risk of cardiovascular disease include:

• Coronary artery calcification

  

• Carotid intima-media thickness
• Carotid total plaque area
• Higher fibrinogen and PAI-1 blood concentrations
• Elevated homocysteine
• Elevated blood levels of asymmetric dimethylarginine
• Inflammation as measured by C-reactive protein
• Elevated Low-density lipoprotein-p
• Elevated blood levels of brain natriuretic peptide (also known as B-type) (BNP)

Prevention

Currently practiced measures to prevent cardiovascular disease include:

• A low-fat, high-fiber diet including whole grains and plenty of fresh fruit and vegetables (at least five portions a day)
• Tobacco cessation and avoidance of second-hand smoke;
• Limit alcohol consumption to the recommended daily limits; consumption of 1-2 standard alcoholic drinks per day may reduce risk by 30% However excessive alcohol intake increases the risk of cardiovascular disease.
• Lower blood pressures, if elevated;
• Decrease body fat (BMI) if overweight or obese;
• Increase daily activity to 30 minutes of vigorous exercise per day at least five times per week;
• Reduce sugar consumptions;
• Decrease psychosocial stress. Stress however plays a relatively minor role in hypertension. Specific relaxation therapies are not supported by the evidence.

For adults without a known diagnosis of hypertension, diabetes, hyperlipidemia, or cardiovascular disease, routine counseling to advise them to improve their diet and increase their physical activity has not been found to significantly alter behaviour, and thus is not recommended.

Diet

Evidence suggests that the Mediterranean diet improves cardiovascular outcomes. This may be by "about 30 percent" in those at high risk. There is also evidence that a Mediterranean diet may be more effective than a low-fat diet in bringing about long-term changes to cardiovascular risk factors (e.g., lower cholesterol level and blood pressure). In clinical trials the DASH diet (high in nuts, fish, fruits and vegetables, and low in sweets, red meat and fat) has been shown to reduce blood pressure, lower total and low density lipoprotein cholesterol and improve metabolic syndrome; but the long term benefits outside the context of a clinical trial have been questioned.

Total fat intake does not appear to be an important risk factor. A diet high in trans fatty acids however does appear to increase rates of cardiovascular disease.

Worldwide, dietary guidelines recommend a reduction in saturated fat. There however is some questions around the effect of saturated fat on cardiovascular disease in the medical literature. A 2012 Cochrane review found suggestive evidence of a small benefit from replacing dietary saturated fat by unsaturated fat. A 2013 meta analysis concludes that substitution with omega 6 linoleic acid (a type of unsaturated fat) may increase cardiovascular risk. Replacement of saturated fats with carbohydrates does not change or may increase risk. Benefits from replacement with polyunsaturated fat appears greatest however supplementation with omega-3 fatty acids (a type of polysaturated fat) does not appear have an effect.

The effect of a low salt diet is unclear. A Cochrane review concluded that any benefit in either hypertensive or normal tensive people is small if present. Additionally, the review suggested a low salt diet may be harmful in those with congestive heart failure. However, the review was criticized particularly for not excluding a trial in heart failure where people had low salt and water levels due to diuretics. When this study is left out the rest of the trials show a trend to benefit.

Another review of dietary salt concluded that there is strong evidence that high dietary salt intake increases blood pressure and worsens hypertension, and that it increases the number of cardiovascular disease events; the latter happens both through the increased blood pressure and, quite likely, through other mechanisms. Moderate evidence was found that high salt intake increased cardiovascular mortality; and some evidence was found for an increase in overall mortality, strokes and left-ventricular hypertrophy.

Supplements

While a healthy diet is beneficial, the effect of antioxidant supplementation (vitamin E, vitamin C, etc.) or vitamins generally has not been shown to improve protection against cardiovascular disease and in some cases may possibly result in harm. Niacin, a type of vitamin B3, may be an exception with a modest decrease in the risk of cardiovascular events in those at high risk. Magnesium supplementation lowers high blood pressure in a dose dependent manner. Magnesium therapy is recommended for patients with ventricular arrhythmia associated with torsade de pointes who present with long QT syndrome as well as for the treatment of patients with digoxin intoxication-induced arrhythmias. Results from an observational study conducted in the general Japanese population demonstrated that lower serum magnesium levels were associated with a greater average intima-media thickness and the risk of at least two carotid plaques. Evidence to support omega-3 fatty acid supplementation is lacking.

Medication

Aspirin has not been found to be of benefit overall in those at low risk of heart disease as the risk of serious bleeding is equal to the benefit with respect to cardiovascular problems.

Statins are effective in preventing further cardiovascular disease in those with a history of cardiovascular disease. As the event rate is higher in men than in women, the decrease in events is more easily seen in men than women. In those without cardiovascular disease but risk factors statins appear to also be beneficial with a decrease in mortality and further heart disease. The time course over which statins provide preventation against death appears to be long, of the order of one year, which is much longer than the duration of their effect on lipids.

Management

Cardiovascular disease is treatable with initial treatment primarily focused on diet and lifestyle interventions.

Epidemiology

Cardiovascular diseases are the leading cause of death. In 2008, 30% of all global death is attributed to cardiovascular diseases. Death caused by cardiovascular diseases are also higher in low and middle-income countries as over 80% of all global death caused by cardiovascular diseases occurred in those countries. It is also estimated that by 2030, over 23 million people will die from cardiovascular diseases annually.

Research

The first studies on cardiovascular health were performed in 1949 by Jerry Morris using occupational health data and were published in 1958. The causes, prevention, and/or treatment of all forms of cardiovascular disease remain active fields of biomedical research, with hundreds of scientific studies being published on a weekly basis.

A fairly recent emphasis is on the link between low-grade inflammation that hallmarks atherosclerosis and its possible interventions. C-reactive protein (CRP) is a common inflammatory marker that has been found to be present in increased levels in patients at risk for cardiovascular disease. Also osteoprotegerin which involved with regulation of a key inflammatory transcription factor called NF-κB has been found to be a risk factor of cardiovascular disease and mortality.

Some areas currently being researched include possible links between infection with Chlamydophila pneumoniae (a major cause of pneumonia) and coronary artery disease. The Chlamydia link has become less plausible with the absence of improvement after antibiotic use.

Several research also investigated the benefits of melatonin on cardiovascular diseases prevention and cure. Melatonin is a pineal gland secretion and it is shown to be able to lower total cholesterol, very low density and low density lipoprotein cholesterol levels in the blood plasma of rats. Reduction of blood pressure is also observed when pharmacological doses are applied. Thus, it is deemed to be a plausible treatment for hypertension. However, further research needs to be conducted to investigate the side effects, optimal dosage and etc. before it can be licensed for use.

References

1. Maton, Anthea (1993). Human Biology and Health. Englewood Cliffs, New Jersey: Prentice Hall. ISBN 0-13-981176-1. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
2. ^ Bridget B. Kelly; Institute of Medicine; Fuster, Valentin (2010). Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health. Washington, D.C: National Academies Press. ISBN 0-309-14774-3.{{cite book}}: CS1 maint: multiple names: authors list (link)
3. Dantas AP, Jimenez-Altayo F, Vila E (2012). "Vascular aging: facts and factors". Frontiers in Vascular Physiology. 3 (325): 1–2. doi:10.3389/fphys.2012.00325. PMID 22934073. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
4. Countries, Committee on Preventing the Global Epidemic of Cardiovascular Disease: Meeting the Challenges in Developing (2010). Promoting cardiovascular health in the developing world : a critical challenge to achieve global health. Washington, D.C.: National Academies Press. pp. Chapter 2. ISBN 978-0-309-14774-3. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
5. Mendis, S.; Puska, P.; Norrving, B.(editors) (2011), Global Atlas on cardiovascular disease prevention and control, ISBN 978-92-4-156437-3 {{citation}}: |first3= has generic name (help)
6. ^ Finegold, JA (2012 Dec 4). "Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations". International journal of cardiology. PMID 23218570. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
7. McGill HC, McMahan CA, Gidding SS (2008). "Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study". Circulation. 117 (9): 1216–27. doi:10.1161/CIRCULATIONAHA.107.717033. PMID 18316498. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
8. "WHO Disease and injury country estimates". World Health Organization. 2009. Retrieved Nov. 11, 2009. {{cite web}}: Check date values in: |accessdate= (help)
9. Howard, BV (2002 Jul 23). "Sugar and cardiovascular disease: A statement for healthcare professionals from the Committee on Nutrition of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association". Circulation. 106 (4): 523–7. PMID 12135957. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
10. Finks, SW (2012 Apr). "Key articles of dietary interventions that influence cardiovascular mortality". Pharmacotherapy. 32 (4): e54-87. PMID 22392596. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
11. Yusuf S, Hawken S, Ounpuu S; et al. (2004). "Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study". Lancet. 364 (9438): 937–52. doi:10.1016/S0140-6736(04)17018-9. PMID 15364185. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
12. "Understand Your Risk of Heart Attack". American Heart Association.http://www.heart.org/HEARTORG/Conditions/HeartAttack/UnderstandYourRiskofHeartAttack/Understand-Your-Risk-of-Heart-Attack_UCM_002040_Article.jsp#
13. Mackay, Mensah, Mendis, et al. The Atlas of Heart Disease and Stroke. World Health Organization. January 2004.
14. ^ Jousilahti Vartiainen, Tuomilehto Puska (1999). "Sex, Age,Cardiovascular Risk Factors, and coronary heart disease". Circulation. 99: 1165–1172.
15. ^ Jani B, Rajkumar C (2006). "Ageing and vascular ageing". Postgrad Med J. 82: 357–362.
16. ^ http://www.world-heart-federation.org/cardiovascular-health/cardiovascular-disease-risk-factors
17. Jackson R, Chambles L, Higgins M, Kuulasmaa K, Wijnberg L, Williams D (WHO MONICA Project, and ARIC Study.) Sex difference in ischaemic heart disease mortality and risk factors in 46 communities: an ecologic analysis. Cardiovasc Risk Factors. 1999; 7:43-54.
18. ^ Khallaf, Mohamed (2011). The Impact of Air Pollution on Health, Economy, Environment and Agricultural Sources. InTech. pp. 69–92. ISBN 978-953-307-528-0.
19. ^ Franchini M, Mannucci PM (2012). "Air pollution and cardiovascular disease". Thrombosis Research. 129 (3): 230–4. doi:10.1016/j.thromres.2011.10.030. PMID 22113148.
20. ^ "Cardiovascular Effects of Ambient Particulate Air Pollution Exposure". Circulation. 121 (25): 2755–65. 2010. doi:10.1161/CIRCULATIONAHA.109.893461. PMC 2924678. PMID 20585020.
21. Vanhecke TE, Miller WM, Franklin BA, Weber JE, McCullough PA (2006). "Awareness, knowledge, and perception of heart disease among adolescents". Eur J Cardiovasc Prev Rehabil. 13 (5): 718–23. doi:10.1097/01.hjr.0000214611.91490.5e. PMID 17001210. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
22. Highlander P, Shaw GP (2010). "Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics". Ther Adv Cardiovasc Dis. 4: 43–54.
23. NPS Medicinewise (1 March 2011). "NPS Prescribing Practice Review 53: Managing lipids". Retrieved 1 August 2011.
24. Kvan E., Pettersen K.I., Sandvik L., Reikvam A. (2007). "High mortality in diabetic patient with acute myocardial infarction: cardiovascular co-morbidities contribute most to the high risk". Int J Cardiol. 121: 184–188.{{cite journal}}: CS1 maint: multiple names: authors list (link)
25. Norhammar A., Malmberg K., Diderhol E., Lagerqvist B., Lindahl B., Ryde; et al. (2004). "Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J". Am Coll Cardiol. 43: 585–591. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
26. DECODE , European Diabetes Epidemiology Group (1999). "Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria". Lancet. 354: 617–621. doi:10.1016/S0140-6736(98)12131-1. PMID 10466661.
27. ^ Moyer, VA (2012 Oct 2). "Screening for coronary heart disease with electrocardiography: U.S. Preventive Services Task Force recommendation statement". Annals of internal medicine. 157 (7): 512–8. doi:10.7326/0003-4819-157-7-201210020-00514. PMID 22847227. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
28. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS (2006). "Multiple biomarkers for the prediction of first major cardiovascular events and death". N. Engl. J. Med. 355 (25): 2631–billy bob joe9. doi:10.1056/NEJMoa055373. PMID 17182988.{{cite journal}}: CS1 maint: multiple names: authors list (link)
29. Spence JD (2006). "Technology Insight: ultrasound measurement of carotid plaque--patient management, genetic research, and therapy evaluation". Nat Clin Pract Neurol. 2 (11): 611–9. doi:10.1038/ncpneuro0324. PMID 17057748.
30. ^ Bertazzo, S. et al. Nano-analytical electron microscopy reveals fundamental insights into human cardiovascular tissue calcification. Nature Materials 12, 576-583 (2013).
31. Inaba, Y (2012 Jan). "Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis". Atherosclerosis. 220 (1): 128–33. doi:10.1016/j.atherosclerosis.2011.06.044. PMID 21764060. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
32. J Clin Lipidol. 2007 Dec;1(6):583-92. doi: 10.1016/j.jacl.2007.10.001. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management.
33. Wang TJ, Larson MG, Levy D; et al. (2004). "Plasma natriuretic peptide levels and the risk of cardiovascular events and death". N Engl J Med. 350 (7): 655–63. doi:10.1056/NEJMoa031994. PMID 14960742. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
34. ^ NHS Direct
35. Ignarro, LJ (2007 Jan 15). "Nutrition, physical activity, and cardiovascular disease: an update". Cardiovascular research. 73 (2): 326–40. doi:10.1016/j.cardiores.2006.06.030. PMID 16945357. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
36. World Heart Federation (5 October 2011). "World Heart Federation: Cardiovascular disease risk factors". Retrieved 5 October 2011.
37. The National Heart, Lung, and Blood Institute (NHLBI) (5 October 2011). "How To Prevent and Control Coronary Heart Disease Risk Factors - NHLBI, NIH". Retrieved 5 October 2011.{{cite web}}: CS1 maint: multiple names: authors list (link)
38. Klatsky AL (2009). "Alcohol and cardiovascular diseases". Expert Rev Cardiovasc Ther. 7 (5): 499–506. doi:10.1586/erc.09.22. PMID 19419257. {{cite journal}}: Unknown parameter |month= ignored (help)
39. McTigue KM, Hess R, Ziouras J (2006). "Obesity in older adults: a systematic review of the evidence for diagnosis and treatment". Obesity (Silver Spring). 14 (9): 1485–97. doi:10.1038/oby.2006.171. PMID 17030958. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
40. Linden W, Stossel C, Maurice J (1996). "Psychosocial interventions for patients with coronary artery disease: a meta-analysis". Arch. Intern. Med. 156 (7): 745–52. PMID 8615707. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
41. Marshall, IJ (2012 Jul 9). "Lay perspectives on hypertension and drug adherence: systematic review of qualitative research". BMJ (Clinical research ed.). 345: e3953. PMC 3392078. PMID 22777025. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
42. Dickinson, HO (2006 Feb). "Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials". Journal of hypertension. 24 (2): 215–33. doi:10.1097/01.hjh.0000199800.72563.26. PMID 16508562. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
43. Moyer, VA (2012 Sep 4). "Behavioral counseling interventions to promote a healthful diet and physical activity for cardiovascular disease prevention in adults: U.S. Preventive Services Task Force recommendation statement". Annals of internal medicine. 157 (5): 367–71. doi:10.7326/0003-4819-157-5-201209040-00486. PMID 22733153. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
44. Walker C, Reamy BV (2009). "Diets for cardiovascular disease prevention: what is the evidence?". Am Fam Physician. 79 (7): 571–8. PMID 19378874. {{cite journal}}: Unknown parameter |month= ignored (help)
45. "Primary Prevention of Cardiovascular Disease with a Mediterranean Diet". New England Journal of Medicine. February 25, 2013. doi:10.1056/NEJMoa1200303. Retrieved February 25, 2013. {{cite journal}}: Unknown parameter |authors= ignored (help)
46. Nordmann, AJ (2011 Sep). "Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors". The American journal of medicine. 124 (9): 841–51.e2. PMID 21854893. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
47. Sacks FM, Svetkey LP, Vollmer WM; et al. (2001). "Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group". N. Engl. J. Med. 344 (1): 3–10. doi:10.1056/NEJM200101043440101. PMID 11136953. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
48. Obarzanek E, Sacks FM, Vollmer WM; et al. (2001). "Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial". Am. J. Clin. Nutr. 74 (1): 80–9. PMID 11451721. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
49. Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi T, Azizi F (2005). "Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome". Diabetes Care. 28 (12): 2823–31. PMID 16306540. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
50. Logan AG (2007). "DASH Diet: time for a critical appraisal?". Am. J. Hypertens. 20 (3): 223–4. doi:10.1016/j.amjhyper.2006.10.006. PMID 17324730. {{cite journal}}: Unknown parameter |month= ignored (help)
51. ^ Willett, WC (2012 Jul). "Dietary fats and coronary heart disease". Journal of internal medicine. 272 (1): 13–24. PMID 22583051. {{cite journal}}: Check date values in: |date= (help)
52. Mozaffarian, D (2009 May). "Health effects of trans-fatty acids: experimental and observational evidence". European journal of clinical nutrition. 63 Suppl 2: S5-21. doi:10.1038/sj.ejcn.1602973. PMID 19424218. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
53. ^ Ramsden, CE (2013 Feb 4). "Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis". BMJ (Clinical research ed.). 346: e8707. PMID 23386268. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
54. Stamler J (2010). "Diet-heart: a problematic revisit". Am. J. Clin. Nutr. 91 (3): 497–9. doi:10.3945/ajcn.2010.29216. PMID 20130097. {{cite journal}}: Unknown parameter |month= ignored (help)
55. Siri-Tarino, PW (2010). "Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease". The American Journal of Clinical Nutrition. 91 (3): 535–46. doi:10.3945/ajcn.2009.27725. PMC 2824152. PMID 20071648. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
56. Hooper, L (2012 May 16). "Reduced or modified dietary fat for preventing cardiovascular disease". Cochrane database of systematic reviews (Online). 5: CD002137. PMID 22592684. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
57. Siri-Tarino Patty W, Sun Qi, Hu Frank B, Krauss Ronald M (2010). "Saturated fat, carbohydrate, and cardiovascular disease". American Journal of Clinical Nutrition. 91 (3): 502–509. doi:10.3945/ajcn.2008.26285. PMC 2824150. PMID 20089734.{{cite journal}}: CS1 maint: multiple names: authors list (link)
58. Micha, R (2010 Oct). "Saturated fat and cardiometabolic risk factors, coronary heart disease, stroke, and diabetes: a fresh look at the evidence". Lipids. 45 (10): 893–905. doi:10.1007/s11745-010-3393-4. PMC 2950931. PMID 20354806. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
59. Astrup, A (2011 Apr). "The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010?". The American journal of clinical nutrition. 93 (4): 684–8. PMID 21270379. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
60. Rizos, EC (2012 Sep 12). "Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis". JAMA : the journal of the American Medical Association. 308 (10): 1024–33. PMID 22968891. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
61. ^ Taylor, RS (2011 Jul 6). "Reduced dietary salt for the prevention of cardiovascular disease". Cochrane database of systematic reviews (Online) (7): CD009217. doi:10.1002/14651858.CD009217. PMID 21735439. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
62. ^ He, F J (2011). "Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials" (PDF). The Lancet. 378: 380–382. doi:10.1016/S0140-6736(11)61174-4. PMID 21803192. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
63. Paterna, S (2008). "Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend?". Clin Sci (Lond). 114: 221–230. doi:10.1042/CS20070193. PMID 17688420. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
64. ^ Bochud, M (2012). "Dietary Salt Intake and Cardiovascular Disease: Summarizing the Evidence". Public Health Reviews. 33: 530–552. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
65. Cook, N R (2007). "Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP)". BMJ: 334. doi:10.1136/bmj.39147.604896.55. PMID 17449506. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
66. Bhupathiraju, SN (2011 Aug 17). "Coronary heart disease prevention: nutrients, foods, and dietary patterns". Clinica chimica acta; international journal of clinical chemistry. 412 (17–18): 1493–514. PMID 21575619. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
67. Myung, SK (2013 Jan 18). "Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials". BMJ (Clinical research ed.). 346: f10. PMC 3548618. PMID 23335472. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
68. Bruckert, E (2010 Jun). "Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis". Atherosclerosis. 210 (2): 353–61. doi:10.1016/j.atherosclerosis.2009.12.023. PMID 20079494. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
69. Lavigne, PM (2013 Jan 29). "The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression". Journal of the American College of Cardiology. 61 (4): 440–6. PMID 23265337. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
70. Jee SH, Miller ER III, Guallar E; et al. (2002). "The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials". Am J Hypertens. 15 (8): 691–696. doi:10.1016/S0895-7061(02)02964-3. PMID 12160191. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
71. Zipes DP, Camm AJ, Borggrefe M; et al. (2012). "ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society" (PDF). Circulation. 114 (10): e385 – e484. doi:10.1161/CIRCULATIONAHA.106.178233. PMID 16935995. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
72. Massy ZA, Drüeke TB (2012). "Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis, and survival" (PDF). Clin Kidney J. 5 (Suppl 1): i52 – i61. doi:10.1093/ndtplus/sfr167.
73. Kwak, SM (2012 Apr 9). "Efficacy of Omega-3 Fatty Acid Supplements (Eicosapentaenoic Acid and Docosahexaenoic Acid) in the Secondary Prevention of Cardiovascular Disease: A Meta-analysis of Randomized, Double-blind, Placebo-Controlled Trials". Archives of Internal Medicine. doi:10.1001/archinternmed.2012.262. PMID 22493407. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
74. Berger, JS (2011 Jul). "Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials". American heart journal. 162 (1): 115–24.e2. doi:10.1016/j.ahj.2011.04.006. PMID 21742097. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
75. ^ Gutierrez, J (2012 Jun 25). "Statin Therapy in the Prevention of Recurrent Cardiovascular Events: A Sex-Based Meta-analysisStatin Therapy to Prevent Recurrent CV Events". Archives of Internal Medicine. 172 (12): 909–19. doi:10.1001/archinternmed.2012.2145. PMID 22732744. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
76. Taylor, F (2013 Jan 31). "Statins for the primary prevention of cardiovascular disease". Cochrane database of systematic reviews (Online). 1: CD004816. PMID 23440795. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
77. Francis, DP (2011 May 19). "Duration and magnitude of the effect of a single statin tablet in primary prevention of cardiovascular events". International journal of cardiology. 149 (1): 102–7. PMID 21183232. {{cite journal}}: Check date values in: |date= (help)
78. Ornish, Dean; et al. (1990). "'Can lifestyle changes reverse coronary heart disease?' The Lifestyle Heart Trial". Lancet. 336 (8708): 129–33. doi:10.1016/0140-6736(90)91656-U. PMID 1973470. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)
79. Ornish, D., Scherwitz, L. W., Doody, R. S., Kesten, D., McLanahan, S. M., Brown, S. E.; et al. (1983). "Effects of stress management training and dietary changes in treating ischemic heart disease". JAMA. 249 (54): 54. doi:10.1001/jama.249.1.54. PMID 6336794. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
80. Ornish, D., Scherwitz, L. W., Billings, J. H., Brown, S. E., Gould, K. L., Merritt, T. A.; et al. (1998). "Intensive lifestyle changes for reversal of coronary heart disease". JAMA. 280 (23): 2001–7. doi:10.1001/jama.280.23.2001. PMID 9863851. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
81. "WHO Disease and injury country estimates". World Health Organization. 2009. Retrieved Nov. 11, 2009. {{cite web}}: Check date values in: |accessdate= (help)
82. Morris J. N., Crawford Margaret D. (1958). "Coronary Heart Disease and Physical Activity of Work". British Medical Journal. 2 (5111): 1485–1496. PMC 2027542. PMID 13608027.
83. Karakas M, Koenig W (2009). "CRP in cardiovascular disease". Herz. 34 (8): 607–13. doi:10.1007/s00059-009-3305-7. PMID 20024640. {{cite journal}}: Unknown parameter |month= ignored (help)
84. 20448212
85. Venuraju SM, Yerramasu A, Corder R, Lahiri A (2010). "Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity". J. Am. Coll. Cardiol. 55 (19): 2049–61. doi:10.1016/j.jacc.2010.03.013. PMID 20447527. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
86. Andraws R, Berger JS, Brown DL (2005). "Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials". JAMA. 293 (21): 2641–7. doi:10.1001/jama.293.21.2641. PMID 15928286. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
87. Dominguez-Rodriguez, Alberto (2012). "Melatonin and Cardiovascular Disease: Myth or Reality?". Rev Esp Cardiol. 65: 215–218. {{cite journal}}: Unknown parameter |month= ignored (help)

External links

• Template:Dmoz
• European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)

Template:Medical conditions

• Heart diseases